Table 1. Baseline clinical characteristics of patients.
| Overall (n = 110) | 15 mg QD (n = 59) | 10 mg QD (n = 51) | P value | |
| Women | 37(34) | 13(22) | 24(47) | 0.008 |
| Age, y | 74.6±9.4 | 68.8±7.4 | 81.4±6.6 | <0.001 |
| Congestive heart failure | 13(12) | 3(5) | 10(20) | 0.035 |
| Hypertension | 70(64) | 36(61) | 34(67) | 0.558 |
| Diabetes mellitus | 29(26) | 15(25) | 14(27) | 0.831 |
| Index cerebrovascular events | 0.949 | |||
| Acute ischemic stroke | 84(76) | 46(78) | 38(74) | |
| Acute TIA | 8(7) | 5(9) | 3(6) | |
| Acute intracerebral hemorrhage | 7(6) | 2(3) | 5(10) | |
| Chronic ischemic stroke | 11(10) | 6(10) | 5(10) | |
| Prior vascular disease | 11(10) | 5(9) | 6(12) | 0.752 |
| CHADS2 | 2(1–3) | 1(1–2) | 2(2–3) | 0.001 |
| CHA2DS2-VASc | 3(2–4) | 2(1–4) | 4(3–5) | 0.001 |
| Weight | 59.1±11.0 | 64.0±9.4 | 53.4±10.0 | <0.001 |
| NIHSS score on admission | 4(2–14) | 4(2–13) | 5(1–15) | 0.727 |
| Concomitant use of antiplatelet agent | 8(7) | 4(7) | 4(8) | 0.831 |
| Creatinine clearance (mL/min) | 61.6±20.0 | 74.0±16.7 | 47.2±12.4 | <0.001 |
| 30–49 mL/min | 37(34) | 0(0) | 37(73) | <0.001 |
| Liver dysfunction | ||||
| Child-Pugh grade B or C | 0(0) | 0(0) | 0(0) | 0.999 |
| Tablet crushing | 15(14) | 5(9) | 10(20) | 0.103 |
| Time from initiation of rivaroxaban to blood sampling, day | 6(5–7) | 6(5–7) | 6(5–8) | 0.625 |
| Time from stroke/TIA onset to blood sampling, day* | 12(8–15)(n = 99) | 12(8–13)(n = 53) | 12(9–15)(n = 46) | 0.212 |
Data are numbers (%), means±SD, or medians (interquartile range). *Patients with chronic ischemic stroke are excluded. TIA, transient ischemic attack; NIHSS, National Institutes of Health Stroke Scale.